Clinical effect of bone marrow combined w ith peripheral blood haploidentical hematopoietic stem cell transp lantation in the treatment of acute leukem ia
XU Xiao-li
Department of Hematology,the First People′s Hospital of Foshan City in Guangdong Province,Foshan 528000,China
Abstract：ObjectiveTo explore the clinical effect of bone marrow combined with peripheral blood haploid-matched hematopoietic stem cell transplantation in the treatment of acute leukemia.MethodsFifty-three patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation in our hospital from January 2007 to January 2016 were retrospectively analyzed.According to different transplantation methods,they were divided into experimental group(22 cases)and control group(31cases).Patients in experimental group were treated with bonemarrow combined with peripheral blood haploid hematopoietic stem cell transplantation,patients in control group were treated with bonemarrow stem cell transplantation,and peripheral blood stem cells in the experimentweremobilized by G-CSF.The recovery of blood cells,incidence of acute graft-versus-host disease(aGVHD),transplantation-related mortality,2 years recurrence rate and survival rate and adverse reaction rate were compared between the two groups.ResultsThe survival rate of patients in the experimental group was higher than that in the control group,while the recurrence rate and incidence rate of aGVHD were lower than that in the control group,the difference was statistically significant(P＜0.05).The blood routine indexes of patients in the experimental group after transplantation and follow-up were higher than those in the control group,and the differencewas statistically significant(P＜0.05).The incidence of adverse events in the experimental group was lower than that in the control group,and the difference was statistically significant(P＜0.05).ConclusionBonemarrow combined with peripheral blood haploidentical hematopoietic stem cell transplantation is of great significance in the treatment of acute leukemia,and can reduce the recurrence rate and incidence of aGVHD on the basis of improving the quality of life.It isworth applying and popularizing.
Peccatori J，Forcina A，Clerici D，et al.Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cellsand permits peripheralblood stem cell transplantation from haploidentical donors[J].Leukemia，2015，29（2）：396.
京公网安备 11010502046607号